ABC Arbitrage SA Invests $3.69 Million in Genmab A/S (NASDAQ:GMAB)

ABC Arbitrage SA bought a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 176,898 shares of the company's stock, valued at approximately $3,692,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GMAB. Two Sigma Advisers LP grew its stake in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after purchasing an additional 280,900 shares in the last quarter. FMR LLC grew its position in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Genmab A/S by 6.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company's stock valued at $5,662,000 after acquiring an additional 14,165 shares during the last quarter. Natixis Advisors LLC raised its position in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after acquiring an additional 47,437 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Genmab A/S by 16.0% during the third quarter. US Bancorp DE now owns 171,669 shares of the company's stock worth $4,185,000 after purchasing an additional 23,723 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GMAB shares. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. BMO Capital Markets reaffirmed an "outperform" rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $42.17.

Genmab A/S Trading Up 0.9 %

GMAB traded up $0.20 during trading hours on Wednesday, hitting $21.97. The company's stock had a trading volume of 1,900,117 shares, compared to its average volume of 1,598,679. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The company has a 50-day simple moving average of $20.64 and a 200 day simple moving average of $22.98. The firm has a market capitalization of $14.54 billion, a PE ratio of 12.63, a PEG ratio of 2.52 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts expect that Genmab A/S will post 1.44 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.